Chronic Cerebrospinal Venous Insufficiency as a Cause of Multiple Sclerosis: Controversy and Reality

  • Claudiu I. Diaconu
  • Devon Conway
  • Robert J. Fox
  • Alexander Rae-Grant
Vascular Disease (H Gornik and E Kim, Section Editors)

Opinion statement

Multiple sclerosis (MS) is a relapsing and progressive disorder of the central nervous system. It is characterized most commonly by episodes of clinical worsening, followed by clinical improvement. Pathologically, MS is associated with focal areas of myelin destruction, inflammation, and axonal transection (“demyelinating plaques”) in the brain and spinal cord. Traditionally, MS has been considered an autoimmune disorder, with the primary pathophysiology arising from an errant immune system. Recent work has raised the possibility that MS is not caused primarily by an immune abnormality but may instead arise from venous anomalies affecting the jugular and/or azygos venous systems. This condition has been called chronic cerebrospinal venous insufficiency (CCSVI). It has been proposed that CCSVI may be pathogenic in MS, causing venous back pressure and iron deposition, with a secondary immune response. Some investigators have proceeded to unblinded nonrandomized angioplasty and stenting procedures in patients with CCSVI, with anecdotal reports of symptom improvement. Because of conflicting data on the presence of CCSVI and the absence of controlled trials of CCSVI intervention, the current standard of clinical care is neither to evaluate multiple sclerosis (MS) patients for CCSVI anomalies, nor to intervene with procedures to alter such anomalies. There is intense interest and ongoing work to evaluate the presence of venous anomalies in MS patients as well as in normal controls and patients with other neurologic conditions; to characterize such anomalies, if present; and to further understand whether the concept of a “backpressure” pathology is borne out by the evidence. If CCSVI is indeed a pathogenic mechanism for some subset of the MS population, this would dramatically change the focus of attention for therapeutic endeavors and monitoring for this population and would bring MS therapeutics firmly into the area of vascular intervention. On the other hand, the history of MS research contains many novel and potentially paradigm-shifting ideas that were later disproved by other investigators.


Multiple sclerosis CCSVI Venous Vascular 

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343:938–52.PubMedCrossRefGoogle Scholar
  2. 2.
    Ramagopalan SV, Dobson R, Meier UC, et al. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010;9:727–39.PubMedCrossRefGoogle Scholar
  3. 3.
    Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707–17.PubMedCrossRefGoogle Scholar
  4. 4.
    Pettinelli CB, McFarlin DE. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J Immunol. 1981;127:1420–3.PubMedGoogle Scholar
  5. 5.
    Ando DG, Clayton J, Kono D, et al. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol. 1989;124:132–43.PubMedCrossRefGoogle Scholar
  6. 6.
    Huseby ES, Liggitt D, Brabb T, et al. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med. 2001;194:669–76.PubMedCrossRefGoogle Scholar
  7. 7.
    Boster A, Ankeny DP, Racke MK. The potential role of B cell-targeted therapies in multiple sclerosis. Drugs. 2010;70:2343–56.PubMedCrossRefGoogle Scholar
  8. 8.
    Kabat EA, Freedman DA, et al. A study of the crystalline albumin, gamma globulin and total protein in the cerebrospinal fluid of 100 cases of multiple sclerosis and in other diseases. Am J Med Sci. 1950;219:55–64.PubMedCrossRefGoogle Scholar
  9. 9.
    Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–88.PubMedCrossRefGoogle Scholar
  10. 10.
    Charcot JM. Histologie de la sclerose en plaques. Gazette Hospital. 1868;41:554–6.Google Scholar
  11. 11.
    Williamson W. Review of the etiology and Pathology of Multiple Sclerosis. M Chron. 1903;4:261.Google Scholar
  12. 12.
    Putnam T. The pathogenesis of multiple sclerosis: a possible vascular factor. N Engl J Med. 1933;209:786–90.CrossRefGoogle Scholar
  13. 13.
    Putnam T. “Encephalitis” and sclerotic plaques produced by venular obstruction. Arch Neurol Psychiatry. 1935;33:929–40.Google Scholar
  14. 14.
    Putnam T. Evidences of vascular occlusion in multiple sclerosis and “encephalomyelitis”. Arch Neurol Psychiatr. 1937;37:1298–321.Google Scholar
  15. 15.
    Macchi G. The pathology of the blood vessels in multiple sclerosis. J Neuropathol Exp Neurol. 1954;13:378–84.PubMedCrossRefGoogle Scholar
  16. 16.
    Schelling F. Damaging venous reflux into the skull or spine: relevance to multiple sclerosis. Med Hypotheses. 1986;21:141–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Adams CW. Perivascular iron deposition and other vascular damage in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1988;51:260–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Haacke EM, Makki M, Ge Y, et al. Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging. 2009;29:537–44.PubMedCrossRefGoogle Scholar
  19. 19.
    Zamboni P, Lanzara S, Mascoli F, et al. Inflammation in venous disease. Int Angiol. 2008;27:361–9.PubMedGoogle Scholar
  20. 20.••
    Zamboni P, Menegatti E, Galeotti R, et al.: The value of cerebral Doppler venous haemodynamics in the assessment of multiple sclerosis. J Neurol Sci 2009; 282:21–7. This is Zamboni’s initial study, in which he defines the ultrasound criteria for CCSVI. The presented results show a strong association of CCSVI with MS.Google Scholar
  21. 21.
    Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–6.PubMedCrossRefGoogle Scholar
  22. 22.••
    Zamboni P, Galeotti R, Menegatti E, et al.: Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80:392–9. This was also one of Zamboni’s initial studies. In addition to presenting ultrasound data, this article also reports results from selective venography of the target veins in CCSVI. The ultrasound technique was reported to always identify subjects with significant stenoses on venography. A negative ultrasound study in a subject always indicated that no stenoses were subsequently found on venography for that subject.Google Scholar
  23. 23.••
    Doepp F, Paul F, Valdueza JM, et al.: No cerebrocervical venous congestion in patients with multiple sclerosis. Ann Neurol 2010; 68:173–83. This study is often cited as one of the first major studies to challenge the association of CCSVI with MS.Google Scholar
  24. 24.
    Sundstrom P, Wahlin A, Ambarki K, et al. Venous and cerebrospinal fluid flow in multiple sclerosis: a case–control study. Ann Neurol. 2010;68:255–9.PubMedCrossRefGoogle Scholar
  25. 25.••
    Zivadinov R, Marr K, Cutter G, et al.: Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology 2011. In the largest CCSVI ultrasound study to date, this group’s results show an increased prevalence of CCSVI in MS and in subjects with other neurologic disease as compared to healthy controls. However, the specificity and sensitivity of CCSVI for MS was only modest, contradictory to Zamboni’s results that showed a sensitivity and specificity of 100%. The authors thus concluded that the results do not support CCSVI as a major contributing factor in the etiology of MS.Google Scholar
  26. 26.
    Khalil M, Enzinger C, Langkammer C, et al. Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult Scler. 2009;15:1048–54.PubMedCrossRefGoogle Scholar
  27. 27.
    Worthington V, Killestein J, Eikelenboom MJ, et al. Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology. 2010;75:1617–22.PubMedCrossRefGoogle Scholar
  28. 28.
    Keir G, Tasdemir N, Thompson EJ. Cerebrospinal fluid ferritin in brain necrosis: evidence for local synthesis. Clin Chim Acta. 1993;216:153–66.PubMedCrossRefGoogle Scholar
  29. 29.
    Wattjes MP, van Oosten BW, de Graaf WL, et al. No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. J Neurol Neurosurg Psychiatry. 2011;82:429–35.PubMedCrossRefGoogle Scholar
  30. 30.
    Yamout B, Herlopian A, Issa Z, et al. Extracranial venous stenosis is an unlikely cause of multiple sclerosis. Mult Scler. 2010;16(11):1341–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Baracchini C, Perini P, Calabrese M, et al. No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset. Ann Neurol. 2011;69:90–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Laupacis A, Lillie E, Dueck A et al. Association between chronic cerebrospinal venous insufficiency and multiple sclerosis: a meta-analysis CMAJ 2011. doi:10.1503/cmaj.111074
  33. 33.••
    Zamboni P, Galeotti R, Menegatti E, et al. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg. 2009;50:1348–58. This is the only paper reporting on the outcome results from a prospective trial of endovascular intervention for CCSVI. The study reported a significant clinical improvement in MS patients with the diagnosis of CCSVI after undergoing balloon angioplasty. However, the study was single-center, open-label, non-randomized and did not have a comparison group (i.e., placebo or other control).Google Scholar
  34. 34.••
    Ludyga T, Kazibudzki M, Simka M, et al. Endovascular treatment for chronic cerebrospinal venous insufficiency: is the procedure safe?. Phlebology. 2010;25:286–95. This study assessed the safety of balloon angioplasty and stent insertion in subjects diagnosed with CCSVI. The results showed no major complications, such as excessive bleeding, venous thrombosis (excluding in-stent thrombosis), stent migration, or injury to nearby structures. The authors concluded that the endovascular interventions for CCSVI are safe.Google Scholar
  35. 35.••
    Petrov I, Grozdinski L., Kaninski G., et al. Safety profile of endovascular treatment for chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Endovasc Ther. 2011;18(3):314–23. This is another study to report safety data on endovascular interventions for CCSVI. There were no major complications from the procedures (angioplasty and stent insertion). Thus, the authors also concluded that the interventions can be safely performed.Google Scholar
  36. 36.
    Lee BB, Bergan J, Gloviczki P, et al. Diagnosis and treatment of venous malformations Consensus Document of the International Union of Phlebology (IUP)-2009. Int Angiol. 2009;28:434–51.PubMedGoogle Scholar
  37. 37.•
    Malagoni AM, Galeotti R, Menegatti E, et al. Is chronic fatigue the symptom of venous insufficiency associated with multiple sclerosis? A longitudinal pilot study. Int Angiol. 2010;29:176–82. This study evaluated the effect of angioplasty for CCSVI stenoses on the symptom of fatigue in MS patients. The results showed a reduction in the perception of chronic fatigue by the subjects, who all received the intervention.Google Scholar
  38. 38.
    Plasmati R, Pastorelli F, Fini N, et al. Chronic cerebrospinal venous insufficiency: report of transcranial magnetic stimulation follow-up study in a patient with multiple sclerosis. Int Angiol. 2010;29:189–92.PubMedGoogle Scholar
  39. 39.
    Khan O, Filippi M, Freedman MS, et al. Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol. 2010;67:286–90.PubMedCrossRefGoogle Scholar
  40. 40.
    Samson K. Experimental multiple sclerosis vascular shunting procedure halted at Stanford. Ann Neurol. 2010;67:A13–5.CrossRefGoogle Scholar
  41. 41.
    del Pilar Cortes Nino Maria, Tampieri D, Melancon D. Endovascular venous procedures for multiple sclerosis? Mult Scler. 2010;16(7):771–2.CrossRefGoogle Scholar
  42. 42.
    Vedantham S, Benenati JF, Kundu S, et al. Interventional endovascular management of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a position statement by the society of interventional radiology, endorsed by the canadian interventional radiology association. J Vasc Interv Radiol. 2010;21:1335–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Reekers JA, Lee MJ, Belli AM. Cardiovascular and interventional radiological society of Europe commentary on the treatment of chronic cerebrospinal venous insufficiency. Cardiovasc Intervent Radiol. 2011;34:1–2.PubMedCrossRefGoogle Scholar
  44. 44.
    Siskin GP, Haskal ZJ, McLennan G, et al. Development of a research agenda for evaluation of interventional therapies for chronic cerebrospinal venous insufficiency: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol. 2011;22:587–93.PubMedCrossRefGoogle Scholar
  45. 45.
    Zivadinov R, Galeotti R, Hojnacki D, et al. Value of MR Venography for Detection of Internal Jugular Vein Anomalies in Multiple Sclerosis: A Pilot Longitudinal Study. Am J Neuroradiol. 2011;32:938–46.PubMedCrossRefGoogle Scholar
  46. 46.•
    Menegatti E, Genova V, Tessari M, et al. The reproducibility of colour Doppler in chronic cerebrospinal venous insufficiency associated with multiple sclerosis. Int Angiol. 2010;29:121–126. This study shows the importance of proper technique for the reproducibility of the ultrasound diagnosis of CCSVI. The results indicated that the intra- and inter-observer reproducibility significantly improved after training of the ultrasound operators by the same trainer—in this case, by Dr. Zamboni.Google Scholar
  47. 47.
    Lu M, Raber L, Baus L, et al.: Ultrasound Evaluations of Chronic Cerebrospinal Venous Insufficiency (CCSVI): Important Factors to Consider [abstract]. Presented at the 2011 Annual Meeting of the American Academy of Neurology; April 9–16, 2011.Google Scholar
  48. 48.
    Horng S, Miller FG. Is placebo surgery unethical? N Engl J Med. 2002;342(2):137–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Claudiu I. Diaconu
    • 1
  • Devon Conway
    • 1
  • Robert J. Fox
    • 1
  • Alexander Rae-Grant
    • 1
  1. 1.Cleveland Clinic, Mellen Center for Multiple Sclerosis Treatment and ResearchClevelandUSA

Personalised recommendations